Optiscan has been featured in Stockhead, The Australian and 11 News Corp mastheads in a Special Report examining the company’s December 2025 quarterly results, highlighting strong momentum across clinical studies, tier-1 partnerships, regulatory preparation and commercial progress as it advances toward planned US FDA submissions in 2026.

The article outlines Optiscan’s strategic three-year collaboration with Australian Clinical Labs, enabling real-world deployment and validation of its InForm within high-throughput pathology workflows. This partnership is expected to support regulatory submissions while strengthening the commercial case for digital pathology through demonstrated workflow efficiencies and cost savings.

Clinical progress during the quarter included the initiation of Optiscan’s first in-human head and neck cancer imaging study at St John of God Murdoch Hospital, alongside continued advancement of its breast cancer margin assessment study at the Royal Melbourne Hospital. Both studies utilise Optiscan’s InVue and InForm systems and are designed to generate clinically relevant data to support future FDA submissions.

The report also highlights international trial preparations in Germany, ongoing engagement with the US FDA to refine regulatory pathways, and product refinements to improve usability, durability and clinical readiness across Optiscan’s platforms. Commercially, the company continues preparations for the launch of its InSpecta veterinary imaging device, alongside a notable increase in customer cash receipts during the quarter.

"Optiscan’s team can be proud of its many achievements over the quarter. The company’s growing list of clinical agreements with a host of tier-1 partners demonstrates the value in the strong ecosystem and relationships we have built over the years," said Optiscan CEO Dr. Camile Farah.

Stockhead – Read the full article here
The Australian – Read the full article here